Form 8-K - Current report:
SEC Accession No. 0001558370-25-010802
Filing Date
2025-08-07
Accepted
2025-08-07 16:53:03
Documents
15
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K chrs-20250807x8k.htm   iXBRL 8-K 39844
2 EX-99.1 chrs-20250807xex99d1.htm EX-99.1 349221
3 GRAPHIC chrs-20250807xex99d1001.jpg GRAPHIC 9923
  Complete submission text file 0001558370-25-010802.txt   548006

Data Files

Seq Description Document Type Size
4 EX-101.SCH chrs-20250807.xsd EX-101.SCH 4125
5 EX-101.DEF chrs-20250807_def.xml EX-101.DEF 3586
6 EX-101.LAB chrs-20250807_lab.xml EX-101.LAB 17204
7 EX-101.PRE chrs-20250807_pre.xml EX-101.PRE 11368
17 EXTRACTED XBRL INSTANCE DOCUMENT chrs-20250807x8k_htm.xml XML 4852
Mailing Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065
Business Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065 (650) 649-3530
Coherus Oncology, Inc. (Filer) CIK: 0001512762 (see all company filings)

EIN.: 273615821 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)